-
ICD-10-CM Codes
›
-
E00-E89
›
-
E20-E35
›
-
E31-
›
-
2023 ICD-10-CM Diagnosis Code E31.20
2023 ICD-10-CM Diagnosis Code E31.20
Multiple endocrine neoplasia [MEN] syndrome, unspecified
2016 2017 2018 2019 2020 2021 2022 2023 Billable/Specific Code
- E31.20 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
- The 2023 edition of ICD-10-CM E31.20 became effective on October 1, 2022.
- This is the American ICD-10-CM version of E31.20 - other international versions of ICD-10 E31.20 may differ.
Applicable To- Multiple endocrine adenomatosis NOS
- Multiple endocrine neoplasia [MEN] syndrome NOS
The following code(s) above
E31.20 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
- Applicable To annotations, or
- Code Also annotations, or
- Code First annotations, or
- Excludes1 annotations, or
- Excludes2 annotations, or
- Includes annotations, or
- Note annotations, or
- Use Additional annotations
that may be applicable to
E31.20:
- E00-E89
2023 ICD-10-CM Range E00-E89
Endocrine, nutritional and metabolic diseasesNote- All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.
Type 1 Excludes- transitory endocrine and metabolic disorders specific to newborn (P70-P74)
Endocrine, nutritional and metabolic diseases - E20-E35
2023 ICD-10-CM Range E20-E35
Disorders of other endocrine glands
Disorders of other endocrine glands - E31
ICD-10-CM Diagnosis Code E31
Polyglandular dysfunction
2016 2017 2018 2019 2020 2021 2022 2023 Non-Billable/Non-Specific Code
Type 1 Excludes- ataxia telangiectasia [Louis-Bar] (G11.3)
- dystrophia myotonica [Steinert] (G71.11)
- pseudohypoparathyroidism (E20.1)
Polyglandular dysfunction - E31.2
ICD-10-CM Diagnosis Code E31.2
Multiple endocrine neoplasia [MEN] syndromes
2016 2017 2018 2019 2020 2021 2022 2023 Non-Billable/Non-Specific Code
Applicable To- Multiple endocrine adenomatosis
Code Also- any associated malignancies and other conditions associated with the syndromes
Multiple endocrine neoplasia [MEN] syndromes
Approximate Synonyms
- Multiple endocrine neoplasia syndrome
- Polyglandular activity in multiple endocrine adenomatosis
Clinical Information
- A group of autosomal dominant diseases characterized by the combined occurrence of tumors involving two or more endocrine glands that secrete peptide hormones or amines. These neoplasias are often benign but can be malignant. They are classified by the endocrine glands involved and the degree of aggressiveness. The two major forms are men1 and men2 with gene mutations on chromosome 11 and chromosome 10, respectively.
- An autosomal dominant inherited neoplastic syndrome characterized by the development of various endocrine neoplasms and abnormalities in various anatomic sites. There are three types recognized: type 1 (men 1), caused by inactivation of the tumor suppressor gene men-1, type 2a (men 2a), caused by mutation of the ret gene, and type 2b (men 2b) also caused by mutation of the ret gene. Patients with men 1 may develop hyperparathyroidism and parathyroid gland adenomas, pituitary gland adenomas, pancreatic islet cell neoplasms, and carcinoid tumors. Patients with men 2a develop medullary thyroid carcinomas, and may also develop pheochromocytomas and parathyroid gland hyperplasia. Patients with men 2b develop medullary thyroid carcinomas and numerous neural defects including neuromas.
- An inherited condition that may result in the development of cancers of the endocrine system. There are several types of multiple endocrine neoplasia syndrome, and patients with each type may develop different types of cancer. The altered genes that cause each type can be detected with a blood test.
- Group of specific, familial syndromes characterized by simultaneous neoplastic transformation of multiple endocrine tissues, typically the parathyroid glands, pancreatic islets, and anterior pituitary.
ICD-10-CM E31.20 is grouped within Diagnostic Related Group(s) (MS-DRG v40.0):
- 643 Endocrine disorders with mcc
- 644 Endocrine disorders with cc
- 645 Endocrine disorders without cc/mcc
Convert E31.20 to ICD-9-CM
Code History
- 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
- 2017 (effective 10/1/2016): No change
- 2018 (effective 10/1/2017): No change
- 2019 (effective 10/1/2018): No change
- 2020 (effective 10/1/2019): No change
- 2021 (effective 10/1/2020): No change
- 2022 (effective 10/1/2021): No change
- 2023 (effective 10/1/2022): No change
ICD-10-CM Codes Adjacent To E31.20
E29.9 Testicular dysfunction, unspecified
E30 Disorders of puberty, not elsewhere classified
E30.8 Other disorders of puberty
E30.9 Disorder of puberty, unspecified
E31 Polyglandular dysfunction
E31.0 Autoimmune polyglandular failure
E31.1 Polyglandular hyperfunction
E31.2 Multiple endocrine neoplasia [MEN] syndromes
E31.20
Multiple endocrine neoplasia [MEN] syndrome, unspecified
E31.21 Multiple endocrine neoplasia [MEN] type I
E31.22 Multiple endocrine neoplasia [MEN] type IIA
E31.23 Multiple endocrine neoplasia [MEN] type IIB
E31.8 Other polyglandular dysfunction
E31.9 Polyglandular dysfunction, unspecified
E32.0 Persistent hyperplasia of thymus
E32.8 Other diseases of thymus
E32.9 Disease of thymus, unspecified
Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.